Please enter a valid ZIP code

NovoSeven® RT responds with
speed to control their bleeds1-3,a


The speed, efficacy, and safety of NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is available in a convenient system designed to streamline the mixing process.1-4

Learn More

aIn patients with hemophilia A or B with inhibitors.

Give him rapid bleed control
in as few as 5 hours1,a-c

Effectively controls muscle bleeds
Effectively controls joint bleeds

a For joint bleeds in patients with hemophilia A or B with inhibitors.

bData from a randomized, double-blind, parallel-group, multicenter study of patients with hemophilia A or B with and without an inhibitor. Patients were given NovoSeven® (Coagulation Factor VIIa [Recombinant]) at dosing intervals of 2 to 3 hours. Efficacy reflects the number of patients reporting excellent, effective, or partially effective results. Response was rated as “excellent” if patient demonstrated definitive relief of pain/tenderness and/or if there was a measurable decrease in the size of the bleed (or arrest of bleeding) in 8 hours or less. An “effective” response was measured by any of these 3 events occurring from 8 to 14 hours; a “partially effective” response either occurred after 14 hours or indicated detectable relief of pain/tenderness or decrease in bleeding.

cMedian of 2 doses.

Learn More

Give him rapid reconstitution —
16x less infusion volume than
pd-aPCC2,5,d

Learn More

Products scaled proportionally from actual size.

pd-aPCC=plasma-derived activated prothrombin complex concentrate.

dIndividual doses are compared and based on an 88-kg

(194-lb) person receiving a single dose for a joint bleed.

Give him rapid infusion time —
up to 18x faster than pd-aPCC2,5

eDosage based on a 75-U/kg dose for a joint
  bleed.

fPatients are cautioned that the maximum injection
 or infusion rate must not exceed 2 units per kg of
 body weight per minute.

Learn More

Rapid access to patient resources

Do you have a patient you think might be right for NovoSeven® RT (Coagulation Factor VIIa [Recombinant])? Find out if your patient is eligible for a free trial.

LEARN MORE

Rooted in effective
bleed control1-3

Reaching to help more patient types
than any other factor product


Learn More
Needleless Adapter Update

Learn important information about the compatibility of MixPro® with needleless adapters used with CVAD, port, and IV lines.

Read More

Dosing Calculator

Find the right dose for your patients with our convenient online calculator.

Calculate

Get More Resources

Explore clinically relevant hematology information
and tools.

Coagulopathy App—FREE
Elective Orthopedic Surgery
Patient Psychosocial Issues

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is a coagulation factor indicated for:

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported.
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT.
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

Warnings and Precautions

Adverse Reactions

Drug Interactions

Please click here for NovoSeven® RT Prescribing Information.

References: 1. Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798. 2. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2015. 3. Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia. 2007;13(5):527-532. 4. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia. 2008;14(5):898-902. 5. Feiba [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2013.